COMP <GO>
SIBN vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
SI-BONE Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SIBN 2
— UNH 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SIBN
LAST: $20.22 (-4.76%) • MKT CAP: $906.2M
balance-sheet
8.73
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
balance-sheet
3.09
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIBN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SIBN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.60% | 88.31% | -8.71 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.30% | 12.38% | -22.68 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.90% | 6.25% | -7.15 | UNH | /fcf-yield <GO> |
| Operating Margin | -11.10% | 5.32% | -16.42 | UNH | /operating-margins <GO> |
| Net Profit Margin | -9.40% | 3.53% | -12.93 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 3.33% | +16.87 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 8.73 | 3.09 | +5.64 | SIBN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 55.1 | -6.80 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $906.2M | $359.43B | -$358.53B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SIBN REV | UNH REV | SIBN GROSS % | UNH GROSS % | SIBN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $200.9M | $447.57B | 79.6% | 88.7% | -$9.1M | $16.07B |
| FY 2024 | $167.2M | $400.28B | 79.0% | 88.3% | -$22.9M | $20.70B |
| FY 2023 | $138.9M | $371.62B | — | 89.6% | -$18.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIBN // BETA —
UNH // BETA 0.33